• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Jornay PM Nighttime Stimulant for Next-Morning Effect

Jornay PM Nighttime Stimulant for Next-Morning Effect

November 1, 2018
Talia Puzantian, PharmD, BCPP
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Talia Puzantian, PharmD, BCPP Dr. Puzantian has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Prescribing bedtime stimulants sounds like a recipe for a bad night’s sleep. But the FDA recently approved Jornay PM, which is an extended release (ER) formulation of methylphenidate that is, in fact, dosed at night.

Approved for kids age 6 and older, Jornay PM has an extremely delayed onset of effect of 10 hours. This means kids can take it at around 8 pm and it won’t actually kick in until about 6 am, so symptom control appears early in the morning. Jornay PM is cleverly formulated. The methylphenidate is delivered using a technology called “Delexis,” a 2-layer drug delivery system that allows no more than 5% of the drug to be absorbed within the first 10 hours. After this initial lag period, controlled release of the drug occurs between 10–24 hours after administration, with peak levels around 14 hours post-dose.

Approval was based on 2 trials. The first was a 6-week study of 43 kids already taking methylphenidate who were switched to Jornay PM (Wigal S et al, 29th Annual US Psychiatric and Mental Health Congress poster 2016). Over 1 week, the Jornay dose was optimized (mean dose 65.6 mg), and then kids were randomized to either continue Jornay or switch to placebo. After 6 weeks, the kids in the Jornay group showed significantly more improvement compared to placebo in both teacher and parent ratings. The second study was a 3-week, randomized, double-blind study in 161 kids with ADHD that also showed significant improvement with Jornay over placebo (Pliszka SR et al, J Child Adolesc Psychopharmacol 2017;27(6):474–482).

Side effects were similar to other methylphenidate formulations, although insomnia was reported in 41% of patients in the open-label phase of the first trial. Moving forward, it will be important to see whether sleep and appetite are problematic vs other medications or placebo. Jornay PM will be available in 20 mg, 40 mg, 60 mg, 80 mg, and 100 mg ER capsules with a dosing range of 20–100 mg QPM. Pricing information is not yet available as the medication won’t hit pharmacy shelves until early 2019.
Child Psychiatry
KEYWORDS adhd news_of_note sleep_disorders
    Puzantian 150x150
    Talia Puzantian, PharmD, BCPP

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024)

    More from this author
    www.thecarlatreport.com
    Issue Date: November 1, 2018
    SUBSCRIBE NOW
    Table Of Contents
    Note From the Editor-in-Chief
    CME Post-Test - ADHD in Children and Adolescents, CCPR, November/December 2018
    Evaluating and Treating Co-Occurring ADHD and Bipolar Disorder
    Becoming Successful Despite ADHD
    Assessing and Treating Violence in Patients
    Is Cannabis Bad for Cognition?
    Jornay PM Nighttime Stimulant for Next-Morning Effect
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2432683359.jpg
      Child Psychiatry

      Hidden Dangers: The Fentanyl Crisis and Teen Overdose Prevention

      The Fentanyl overdose crisis is now one of the leading causes of death among adolescents, and it is happening in every corner of the country. Stay with us as we talk about the...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.